SK5312002A3 - Sodium-hydrogen exchanger type 1 inhibitor crystals - Google Patents

Sodium-hydrogen exchanger type 1 inhibitor crystals Download PDF

Info

Publication number
SK5312002A3
SK5312002A3 SK531-2002A SK5312002A SK5312002A3 SK 5312002 A3 SK5312002 A3 SK 5312002A3 SK 5312002 A SK5312002 A SK 5312002A SK 5312002 A3 SK5312002 A3 SK 5312002A3
Authority
SK
Slovakia
Prior art keywords
tissue
give
crystal
rel
pharmaceutical composition
Prior art date
Application number
SK531-2002A
Other languages
English (en)
Slovak (sk)
Inventor
Lyle Robinson Brostrom
Terrence Joseph Connolly
Zheng Jane Li
Susan Lee Orrill
Bharat Kiritkumar Shah
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of SK5312002A3 publication Critical patent/SK5312002A3/sk

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Endocrinology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Toxicology (AREA)
  • Surgery (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Emergency Medicine (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Treatment Of Water By Ion Exchange (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
SK531-2002A 1999-10-29 2000-10-09 Sodium-hydrogen exchanger type 1 inhibitor crystals SK5312002A3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US16237499P 1999-10-29 1999-10-29
PCT/IB2000/001460 WO2001030759A2 (en) 1999-10-29 2000-10-09 Sodium-hydrogen exchanger type 1 inhibitor crystals

Publications (1)

Publication Number Publication Date
SK5312002A3 true SK5312002A3 (en) 2003-01-09

Family

ID=22585355

Family Applications (1)

Application Number Title Priority Date Filing Date
SK531-2002A SK5312002A3 (en) 1999-10-29 2000-10-09 Sodium-hydrogen exchanger type 1 inhibitor crystals

Country Status (44)

Country Link
EP (1) EP1224179B1 (es)
JP (1) JP2003512455A (es)
KR (1) KR100464526B1 (es)
CN (2) CN1636991A (es)
AP (1) AP2002002493A0 (es)
AR (1) AR029402A1 (es)
AT (1) ATE271047T1 (es)
AU (1) AU778573B2 (es)
BG (1) BG106729A (es)
BR (1) BR0015275A (es)
CA (1) CA2389020A1 (es)
CO (1) CO5271714A1 (es)
CZ (1) CZ20021332A3 (es)
DE (1) DE60012208T2 (es)
DK (1) DK1224179T3 (es)
DZ (1) DZ3463A1 (es)
EA (1) EA004937B1 (es)
EE (1) EE200200227A (es)
ES (1) ES2222923T3 (es)
GE (1) GEP20043222B (es)
GT (1) GT200000180A (es)
HK (1) HK1048472B (es)
HR (1) HRP20020366B1 (es)
HU (1) HUP0204009A3 (es)
IL (1) IL148581A0 (es)
IS (1) IS6302A (es)
MA (1) MA26840A1 (es)
MX (1) MXPA02004358A (es)
NO (1) NO20021821L (es)
NZ (1) NZ517738A (es)
OA (1) OA12080A (es)
PA (1) PA8505501A1 (es)
PE (1) PE20010764A1 (es)
PL (1) PL354869A1 (es)
PT (1) PT1224179E (es)
SI (1) SI1224179T1 (es)
SK (1) SK5312002A3 (es)
SV (1) SV2002000209A (es)
TN (1) TNSN00210A1 (es)
TR (1) TR200201167T2 (es)
UA (1) UA72002C2 (es)
WO (1) WO2001030759A2 (es)
YU (1) YU31502A (es)
ZA (1) ZA200203295B (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6441176B1 (en) 1999-10-29 2002-08-27 Pfizer Inc. Method for preparing sodium-hydrogen exchanger type 1 inhibitor
RU2242472C1 (ru) * 2001-01-31 2004-12-20 Пфайзер Продактс Инк. Этаноляты n-(5-циклопропил-1-хинолин-5-ил-1н-пиразол-4-карбонил)гуанидина, способ их получения, фармацевтическая композиция на основе этих соединений и способ получения мезилатной соли n-(5-циклопропил-1-хинолин-5-ил-1н-пиразол-4-карбонил)гуанидина
CA2472342A1 (en) * 2002-01-30 2003-08-07 Pfizer Products Inc. Zoniporide mesylate pharmaceutical compositions and processes for improving solubility of zoniporide
MXPA04008646A (es) * 2002-05-02 2004-12-06 Pfizer Prod Inc Tratamiento para la diabetes y complicaciones diabeticas con inhibidores del nhe-1.

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU739403B2 (en) * 1998-02-27 2001-10-11 Pfizer Products Inc. N-((substituted five-membered di- or triaza diunsaturated ring)carbonyl) guanidine derivatives for the treatment of ischemia

Also Published As

Publication number Publication date
NO20021821D0 (no) 2002-04-18
AP2002002493A0 (en) 2002-06-30
ATE271047T1 (de) 2004-07-15
CZ20021332A3 (cs) 2002-10-16
DE60012208T2 (de) 2005-07-21
HRP20020366A2 (en) 2004-02-29
JP2003512455A (ja) 2003-04-02
OA12080A (en) 2003-08-25
GT200000180A (es) 2002-04-11
CN1384829A (zh) 2002-12-11
SV2002000209A (es) 2002-07-16
BG106729A (bg) 2002-12-29
WO2001030759A3 (en) 2001-09-13
NZ517738A (en) 2005-06-24
HK1048472A1 (en) 2003-04-04
HUP0204009A2 (hu) 2003-03-28
KR20020040918A (ko) 2002-05-30
HK1048472B (zh) 2005-09-16
SI1224179T1 (en) 2004-10-31
CN1636991A (zh) 2005-07-13
CO5271714A1 (es) 2003-04-30
AU778573B2 (en) 2004-12-09
PA8505501A1 (es) 2003-09-05
KR100464526B1 (ko) 2005-01-03
PT1224179E (pt) 2004-10-29
ES2222923T3 (es) 2005-02-16
PL354869A1 (en) 2004-03-08
BR0015275A (pt) 2002-07-16
UA72002C2 (en) 2005-01-17
YU31502A (sh) 2004-12-31
DK1224179T3 (da) 2004-10-25
EA200200416A1 (ru) 2002-10-31
EE200200227A (et) 2003-06-16
AR029402A1 (es) 2003-06-25
GEP20043222B (en) 2004-04-26
EA004937B1 (ru) 2004-10-28
PE20010764A1 (es) 2001-07-23
MXPA02004358A (es) 2002-11-07
IL148581A0 (en) 2002-09-12
TNSN00210A1 (fr) 2005-11-10
HRP20020366B1 (en) 2005-04-30
ZA200203295B (en) 2003-06-25
AU7441500A (en) 2001-05-08
EP1224179B1 (en) 2004-07-14
MA26840A1 (fr) 2004-12-20
WO2001030759A2 (en) 2001-05-03
NO20021821L (no) 2002-04-18
DE60012208D1 (de) 2004-08-19
IS6302A (is) 2002-03-15
HUP0204009A3 (en) 2004-07-28
DZ3463A1 (fr) 2001-05-03
TR200201167T2 (tr) 2002-08-21
CA2389020A1 (en) 2001-05-03
EP1224179A2 (en) 2002-07-24
CN1205205C (zh) 2005-06-08

Similar Documents

Publication Publication Date Title
EP3046917B1 (en) Quinazoline derivatives and their use as dna methyltransferase inhibitors
KR100201515B1 (ko) 1-(치환된 피리디닐아미노)-1에이치-인돌-5-일 치환된 카바메이트, 이의 제조방법 및 이를 포함하는 약제학적 조성물
SK5312002A3 (en) Sodium-hydrogen exchanger type 1 inhibitor crystals
BE1014454A6 (nl) Amlodipinehemimaleaat.
SK14872002A3 (sk) Inhibítor sodíko-vodíkových vymieňačov typu 1
JP3712529B2 (ja) ３，３−ジピリジルアクリル酸アミド誘導体又はその薬学的に許容される塩
RU2190605C2 (ru) Способ получения мономезилатной соли n-(5-циклопропил-1-хинолин-5-ил-1н-пиразол-4-карбонил)гуанидина
CN114502161B (zh) 具有心肌细胞增殖活性的杂环衍生物在治疗心脏病中的用途
SK175999A3 (en) Angiogenesis inhibiting 5-substituted-1,2,4-thiadiazolyl derivatives
TW202334114A (zh) 1-磺醯基吡咯衍生物之新穎鹽類、其製備方法及包含其之醫藥組合物
AU2005201428A1 (en) Method for preparing sodium-hydrogen exchanger type 1 inhibitor
WO2019072130A1 (zh) 一种1,2,4-三氮唑类化合物
US20010051634A1 (en) Sodium-hydrogen exchanger type 1 inhibitor
CS249525B2 (cs) Způsob výroby dihydropyridinů